|
|
| This month: The cathepsin K inhibitor odanacatib, a novel approach to the treatment of osteoporosis |
 |
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
235th ACS National Meeting
New Orleans, LA,
6-10 April 2008
Visit us at booth 400 and find out more about Prous Science Integrity new developments. |
|
|
|
|
  Available:
Webcasts from the European Association of Urology (EAU)
March 26 - 29, 2008
Milan, Italy |
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anxiety Targetscape:
A comprehensive network of molecular and cellular connections among the current therapeutic targets for the treatment of anxiety, and their biological actions |
|
|
|
|
 BWH Cardiovascular Grand Rounds Online
Evidence-Based Management of Aortic Valve Disease
Robert O. Bonow,
Chief, Division of Cardiology, Northwestern University Medical School |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Drugs of the Future
mGluR5 positive allosteric modulators may have exciting potential for the treatment of multiple psychiatric and neurological disorders.
|
|
|
Drug News & Perspectives
Targeting biological pathways in abdominal aortic aneurysm (AAA), a complex multifactorial disease with life-threatening implications, may benefit patients by slowing the growth and possibly preventing the rupture of AAA.
|
|
|
|
